Copyright Reports & Markets. All rights reserved.

Global Measurable Residual Disease Testing Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Measurable Residual Disease Testing by Type
    • 1.3.1 Overview: Global Measurable Residual Disease Testing Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Measurable Residual Disease Testing Consumption Value Market Share by Type in 2025
    • 1.3.3 Flow Cytometry
    • 1.3.4 Polymerase Chain Reaction (PCR)
    • 1.3.5 Next-Generation Sequencing (NGS)
    • 1.3.6 Other
  • 1.4 Global Measurable Residual Disease Testing Market by Application
    • 1.4.1 Overview: Global Measurable Residual Disease Testing Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hematological Malignancies
    • 1.4.3 Leukemia
    • 1.4.4 Lymphoma
    • 1.4.5 Solid Tumors
    • 1.4.6 Other
  • 1.5 Global Measurable Residual Disease Testing Market Size & Forecast
  • 1.6 Global Measurable Residual Disease Testing Market Size and Forecast by Region
    • 1.6.1 Global Measurable Residual Disease Testing Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Measurable Residual Disease Testing Market Size by Region, (2021-2032)
    • 1.6.3 North America Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
    • 1.6.6 South America Measurable Residual Disease Testing Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Measurable Residual Disease Testing Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Adaptive Biotechnologies Corporation
    • 2.1.1 Adaptive Biotechnologies Corporation Details
    • 2.1.2 Adaptive Biotechnologies Corporation Major Business
    • 2.1.3 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Product and Solutions
    • 2.1.4 Adaptive Biotechnologies Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Adaptive Biotechnologies Corporation Recent Developments and Future Plans
  • 2.2 ArcherDX, Inc. (Invitae Corporation)
    • 2.2.1 ArcherDX, Inc. (Invitae Corporation) Details
    • 2.2.2 ArcherDX, Inc. (Invitae Corporation) Major Business
    • 2.2.3 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Product and Solutions
    • 2.2.4 ArcherDX, Inc. (Invitae Corporation) Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 ArcherDX, Inc. (Invitae Corporation) Recent Developments and Future Plans
  • 2.3 Asuragen
    • 2.3.1 Asuragen Details
    • 2.3.2 Asuragen Major Business
    • 2.3.3 Asuragen Measurable Residual Disease Testing Product and Solutions
    • 2.3.4 Asuragen Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Asuragen Recent Developments and Future Plans
  • 2.4 Arup Laboratories
    • 2.4.1 Arup Laboratories Details
    • 2.4.2 Arup Laboratories Major Business
    • 2.4.3 Arup Laboratories Measurable Residual Disease Testing Product and Solutions
    • 2.4.4 Arup Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Arup Laboratories Recent Developments and Future Plans
  • 2.5 Bio-Rad Laboratories
    • 2.5.1 Bio-Rad Laboratories Details
    • 2.5.2 Bio-Rad Laboratories Major Business
    • 2.5.3 Bio-Rad Laboratories Measurable Residual Disease Testing Product and Solutions
    • 2.5.4 Bio-Rad Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Bio-Rad Laboratories Recent Developments and Future Plans
  • 2.6 Cergentis B.V.
    • 2.6.1 Cergentis B.V. Details
    • 2.6.2 Cergentis B.V. Major Business
    • 2.6.3 Cergentis B.V. Measurable Residual Disease Testing Product and Solutions
    • 2.6.4 Cergentis B.V. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Cergentis B.V. Recent Developments and Future Plans
  • 2.7 F. Hoffmann- La Roche Ltd
    • 2.7.1 F. Hoffmann- La Roche Ltd Details
    • 2.7.2 F. Hoffmann- La Roche Ltd Major Business
    • 2.7.3 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Product and Solutions
    • 2.7.4 F. Hoffmann- La Roche Ltd Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 F. Hoffmann- La Roche Ltd Recent Developments and Future Plans
  • 2.8 Guardant Health
    • 2.8.1 Guardant Health Details
    • 2.8.2 Guardant Health Major Business
    • 2.8.3 Guardant Health Measurable Residual Disease Testing Product and Solutions
    • 2.8.4 Guardant Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Guardant Health Recent Developments and Future Plans
  • 2.9 ICON plc
    • 2.9.1 ICON plc Details
    • 2.9.2 ICON plc Major Business
    • 2.9.3 ICON plc Measurable Residual Disease Testing Product and Solutions
    • 2.9.4 ICON plc Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 ICON plc Recent Developments and Future Plans
  • 2.10 Invivoscribe
    • 2.10.1 Invivoscribe Details
    • 2.10.2 Invivoscribe Major Business
    • 2.10.3 Invivoscribe Measurable Residual Disease Testing Product and Solutions
    • 2.10.4 Invivoscribe Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Invivoscribe Recent Developments and Future Plans
  • 2.11 Laboratory Corporation of America Holdings
    • 2.11.1 Laboratory Corporation of America Holdings Details
    • 2.11.2 Laboratory Corporation of America Holdings Major Business
    • 2.11.3 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Product and Solutions
    • 2.11.4 Laboratory Corporation of America Holdings Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Laboratory Corporation of America Holdings Recent Developments and Future Plans
  • 2.12 Mission Bio
    • 2.12.1 Mission Bio Details
    • 2.12.2 Mission Bio Major Business
    • 2.12.3 Mission Bio Measurable Residual Disease Testing Product and Solutions
    • 2.12.4 Mission Bio Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Mission Bio Recent Developments and Future Plans
  • 2.13 Natera, Inc.
    • 2.13.1 Natera, Inc. Details
    • 2.13.2 Natera, Inc. Major Business
    • 2.13.3 Natera, Inc. Measurable Residual Disease Testing Product and Solutions
    • 2.13.4 Natera, Inc. Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Natera, Inc. Recent Developments and Future Plans
  • 2.14 NeoGenomics Laboratories
    • 2.14.1 NeoGenomics Laboratories Details
    • 2.14.2 NeoGenomics Laboratories Major Business
    • 2.14.3 NeoGenomics Laboratories Measurable Residual Disease Testing Product and Solutions
    • 2.14.4 NeoGenomics Laboratories Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 NeoGenomics Laboratories Recent Developments and Future Plans
  • 2.15 Opko Health
    • 2.15.1 Opko Health Details
    • 2.15.2 Opko Health Major Business
    • 2.15.3 Opko Health Measurable Residual Disease Testing Product and Solutions
    • 2.15.4 Opko Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Opko Health Recent Developments and Future Plans
  • 2.16 Quest Diagnostics Incorporated
    • 2.16.1 Quest Diagnostics Incorporated Details
    • 2.16.2 Quest Diagnostics Incorporated Major Business
    • 2.16.3 Quest Diagnostics Incorporated Measurable Residual Disease Testing Product and Solutions
    • 2.16.4 Quest Diagnostics Incorporated Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Quest Diagnostics Incorporated Recent Developments and Future Plans
  • 2.17 Sysmex Corporation
    • 2.17.1 Sysmex Corporation Details
    • 2.17.2 Sysmex Corporation Major Business
    • 2.17.3 Sysmex Corporation Measurable Residual Disease Testing Product and Solutions
    • 2.17.4 Sysmex Corporation Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Sysmex Corporation Recent Developments and Future Plans
  • 2.18 Genetron Health
    • 2.18.1 Genetron Health Details
    • 2.18.2 Genetron Health Major Business
    • 2.18.3 Genetron Health Measurable Residual Disease Testing Product and Solutions
    • 2.18.4 Genetron Health Measurable Residual Disease Testing Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Genetron Health Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Measurable Residual Disease Testing Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Measurable Residual Disease Testing by Company Revenue
    • 3.2.2 Top 3 Measurable Residual Disease Testing Players Market Share in 2025
    • 3.2.3 Top 6 Measurable Residual Disease Testing Players Market Share in 2025
  • 3.3 Measurable Residual Disease Testing Market: Overall Company Footprint Analysis
    • 3.3.1 Measurable Residual Disease Testing Market: Region Footprint
    • 3.3.2 Measurable Residual Disease Testing Market: Company Product Type Footprint
    • 3.3.3 Measurable Residual Disease Testing Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Measurable Residual Disease Testing Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Measurable Residual Disease Testing Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Measurable Residual Disease Testing Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Measurable Residual Disease Testing Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
  • 6.2 North America Measurable Residual Disease Testing Market Size by Application (2021-2032)
  • 6.3 North America Measurable Residual Disease Testing Market Size by Country
    • 6.3.1 North America Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
    • 6.3.2 United States Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
  • 7.2 Europe Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
  • 7.3 Europe Measurable Residual Disease Testing Market Size by Country
    • 7.3.1 Europe Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 7.3.3 France Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Measurable Residual Disease Testing Market Size by Region
    • 8.3.1 Asia-Pacific Measurable Residual Disease Testing Consumption Value by Region (2021-2032)
    • 8.3.2 China Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 8.3.5 India Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
  • 9.2 South America Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
  • 9.3 South America Measurable Residual Disease Testing Market Size by Country
    • 9.3.1 South America Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Measurable Residual Disease Testing Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Measurable Residual Disease Testing Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Measurable Residual Disease Testing Market Size by Country
    • 10.3.1 Middle East & Africa Measurable Residual Disease Testing Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Measurable Residual Disease Testing Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Measurable Residual Disease Testing Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Measurable Residual Disease Testing Market Drivers
  • 11.2 Measurable Residual Disease Testing Market Restraints
  • 11.3 Measurable Residual Disease Testing Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Measurable Residual Disease Testing Industry Chain
  • 12.2 Measurable Residual Disease Testing Upstream Analysis
  • 12.3 Measurable Residual Disease Testing Midstream Analysis
  • 12.4 Measurable Residual Disease Testing Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Measurable Residual Disease Testing market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.
    This report is a detailed and comprehensive analysis for global Measurable Residual Disease Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Measurable Residual Disease Testing market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Measurable Residual Disease Testing market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Measurable Residual Disease Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Measurable Residual Disease Testing market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Measurable Residual Disease Testing
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Measurable Residual Disease Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health, ICON plc, Invivoscribe, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Measurable Residual Disease Testing market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Flow Cytometry
    Polymerase Chain Reaction (PCR)
    Next-Generation Sequencing (NGS)
    Other
    Market segment by Application
    Hematological Malignancies
    Leukemia
    Lymphoma
    Solid Tumors
    Other
    Market segment by players, this report covers
    Adaptive Biotechnologies Corporation
    ArcherDX, Inc. (Invitae Corporation)
    Asuragen
    Arup Laboratories
    Bio-Rad Laboratories
    Cergentis B.V.
    F. Hoffmann- La Roche Ltd
    Guardant Health
    ICON plc
    Invivoscribe
    Laboratory Corporation of America Holdings
    Mission Bio
    Natera, Inc.
    NeoGenomics Laboratories
    Opko Health
    Quest Diagnostics Incorporated
    Sysmex Corporation
    Genetron Health
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Measurable Residual Disease Testing product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Measurable Residual Disease Testing, with revenue, gross margin, and global market share of Measurable Residual Disease Testing from 2021 to 2026.
    Chapter 3, the Measurable Residual Disease Testing competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Measurable Residual Disease Testing market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Measurable Residual Disease Testing.
    Chapter 13, to describe Measurable Residual Disease Testing research findings and conclusion.

    Buy now